JP2015520763A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520763A5 JP2015520763A5 JP2015513217A JP2015513217A JP2015520763A5 JP 2015520763 A5 JP2015520763 A5 JP 2015520763A5 JP 2015513217 A JP2015513217 A JP 2015513217A JP 2015513217 A JP2015513217 A JP 2015513217A JP 2015520763 A5 JP2015520763 A5 JP 2015520763A5
- Authority
- JP
- Japan
- Prior art keywords
- cdb
- administered
- breast
- breast tumor
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 229960000499 ulipristal acetate Drugs 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 4
- 102000036365 BRCA1 Human genes 0.000 claims 1
- 108700040618 BRCA1 Genes Proteins 0.000 claims 1
- 101150072950 BRCA1 gene Proteins 0.000 claims 1
- 108700010154 BRCA2 Genes Proteins 0.000 claims 1
- 101150008921 Brca2 gene Proteins 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 3
- 229960003248 mifepristone Drugs 0.000 description 3
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 3
- 229950011093 onapristone Drugs 0.000 description 3
- HKDLNTKNLJPAIY-DWWOYTEKSA-N (8s,13s,14s,17r)-17-acetyl-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1C1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)C(C)=O)[C@]2(C)C1 HKDLNTKNLJPAIY-DWWOYTEKSA-N 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 230000000708 anti-progestin effect Effects 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305586 | 2012-05-25 | ||
| EP12305586.5 | 2012-05-25 | ||
| PCT/EP2013/060801 WO2013175009A1 (en) | 2012-05-25 | 2013-05-24 | Ulipristal acetate for prevention and treatment of breast tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520763A JP2015520763A (ja) | 2015-07-23 |
| JP2015520763A5 true JP2015520763A5 (cg-RX-API-DMAC7.html) | 2016-07-14 |
| JP6322623B2 JP6322623B2 (ja) | 2018-05-09 |
Family
ID=48471021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513217A Expired - Fee Related JP6322623B2 (ja) | 2012-05-25 | 2013-05-24 | 乳房腫瘍の予防および処置のための酢酸ウリプリスタル |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150133418A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2854817B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6322623B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150039130A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013265163B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2874530A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2672727T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE037889T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL235847B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013175009A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017216637A2 (en) | 2017-08-04 | 2017-12-21 | Alvogen Malta Operations (Row) Ltd | Tablet form including ulipristal acetate and the methods for its preparation |
| KR102864826B1 (ko) | 2023-02-07 | 2025-09-29 | 재단법인 아산사회복지재단 | 항암제에 대한 치료 반응성을 예측하기 위한 조성물 및 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| US5747282A (en) | 1994-08-12 | 1998-05-05 | Myraid Genetics, Inc. | 17Q-linked breast and ovarian cancer susceptibility gene |
| US5929262A (en) | 1995-03-30 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates |
| US5965377A (en) | 1997-03-24 | 1999-10-12 | Baystate Medical Center | Method for determining the presence of mutated BRCA protein |
| US6514713B1 (en) | 2001-07-03 | 2003-02-04 | Hybritech Incorporated | Methods of detecting BRCA1 mutations |
| ES2212912B1 (es) | 2003-01-22 | 2005-10-01 | Crystal Pharma, S.A. | Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona. |
| CA2516319C (en) | 2003-02-28 | 2012-09-18 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Method for preparing 17.alpha.-acetoxy-11.beta.-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates |
| WO2007103510A2 (en) * | 2006-03-08 | 2007-09-13 | Danco Laboratories Llc | Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders |
| US8512745B2 (en) | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
-
2013
- 2013-05-24 CA CA2874530A patent/CA2874530A1/en not_active Abandoned
- 2013-05-24 ES ES13724304.4T patent/ES2672727T3/es active Active
- 2013-05-24 US US14/403,304 patent/US20150133418A1/en not_active Abandoned
- 2013-05-24 KR KR1020147036629A patent/KR20150039130A/ko not_active Abandoned
- 2013-05-24 HU HUE13724304A patent/HUE037889T2/hu unknown
- 2013-05-24 AU AU2013265163A patent/AU2013265163B2/en not_active Ceased
- 2013-05-24 WO PCT/EP2013/060801 patent/WO2013175009A1/en not_active Ceased
- 2013-05-24 EP EP13724304.4A patent/EP2854817B1/en not_active Not-in-force
- 2013-05-24 JP JP2015513217A patent/JP6322623B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-23 IL IL235847A patent/IL235847B/en not_active IP Right Cessation
-
2016
- 2016-07-29 US US15/223,066 patent/US9814732B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017039771A5 (cg-RX-API-DMAC7.html) | ||
| JP2019534308A5 (cg-RX-API-DMAC7.html) | ||
| JP2020509024A5 (cg-RX-API-DMAC7.html) | ||
| JP2016517434A5 (cg-RX-API-DMAC7.html) | ||
| JP2013520971A5 (cg-RX-API-DMAC7.html) | ||
| EP2785349A1 (en) | Combination treatment of cancer | |
| JP2019530713A5 (cg-RX-API-DMAC7.html) | ||
| JP2018184465A5 (cg-RX-API-DMAC7.html) | ||
| JP2020522549A5 (cg-RX-API-DMAC7.html) | ||
| CN104688720A (zh) | 绿原酸在制备治疗黑色素瘤的药物中的用途及治疗黑色素瘤的药物 | |
| JP2019530648A5 (cg-RX-API-DMAC7.html) | ||
| JP2019526632A5 (cg-RX-API-DMAC7.html) | ||
| CN101700247A (zh) | 利用脱氢表雄酮甾体及抗毒蕈碱药物治疗呼吸道疾病及肺病的组合物、制剂和试剂盒 | |
| JP2015520763A5 (cg-RX-API-DMAC7.html) | ||
| JP2017516829A5 (cg-RX-API-DMAC7.html) | ||
| JP2017516828A5 (cg-RX-API-DMAC7.html) | ||
| WO2005084387A3 (en) | Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer | |
| Master et al. | Autologous dendritic vaccine therapy in metastatic kidney cancer: the ADAPT trial and beyond | |
| Bergmann et al. | A prospective randomized phase-II trial with temsirolimus vs. sunitinib in non-clear renal cell carcinoma | |
| CN104225463B (zh) | 一种用于治疗激素依赖性肿瘤的中药组合物及其制备方法 | |
| CN104940259B (zh) | 康定独活或其提取物在制备促凝血类药物中的用途 | |
| CA2576926A1 (en) | Use of midostaurin for treating gastrointestinal stromal tumors | |
| CN101579389A (zh) | 一种治疗骨质疏松症的药物组合物 | |
| WO2019104587A1 (zh) | 一种药物组合物及其用途 | |
| Massarelli et al. | P14. 04 A Phase 2 Multicenter Study of Iovance Autologous Tumor Infiltrating Lymphocytes (TIL, LN-145) Cell Therapy in Patients With Metastatic NSCLC |